These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
12. Human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine for the prevention of cervical cancer and HPV-related diseases. Skinner SR; Apter D; De Carvalho N; Harper DM; Konno R; Paavonen J; Romanowski B; Roteli-Martins C; Burlet N; Mihalyi A; Struyf F Expert Rev Vaccines; 2016; 15(3):367-87. PubMed ID: 26902666 [TBL] [Abstract][Full Text] [Related]
13. Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women. Paavonen J; Naud P; Salmerón J; Wheeler CM; Chow SN; Apter D; Kitchener H; Castellsague X; Teixeira JC; Skinner SR; Hedrick J; Jaisamrarn U; Limson G; Garland S; Szarewski A; Romanowski B; Aoki FY; Schwarz TF; Poppe WA; Bosch FX; Jenkins D; Hardt K; Zahaf T; Descamps D; Struyf F; Lehtinen M; Dubin G; Lancet; 2009 Jul; 374(9686):301-14. PubMed ID: 19586656 [TBL] [Abstract][Full Text] [Related]
14. Safety and immunogenicity of human papillomavirus-16/18 AS04-adjuvanted vaccine: a randomized trial in 10-25-year-old HIV-Seronegative African girls and young women. Sow PS; Watson-Jones D; Kiviat N; Changalucha J; Mbaye KD; Brown J; Bousso K; Kavishe B; Andreasen A; Toure M; Kapiga S; Mayaud P; Hayes R; Lebacq M; Herazeh M; Thomas F; Descamps D J Infect Dis; 2013 Jun; 207(11):1753-63. PubMed ID: 23242542 [TBL] [Abstract][Full Text] [Related]
15. Randomized trial of the immunogenicity and safety of the Hepatitis B vaccine given in an accelerated schedule coadministered with the human papillomavirus type 16/18 AS04-adjuvanted cervical cancer vaccine. Leroux-Roels G; Haelterman E; Maes C; Levy J; De Boever F; Licini L; David MP; Dobbelaere K; Descamps D Clin Vaccine Immunol; 2011 Sep; 18(9):1510-8. PubMed ID: 21734063 [TBL] [Abstract][Full Text] [Related]
16. AS04-adjuvanted human papillomavirus-16/18 vaccination: recent advances in cervical cancer prevention. Schwarz TF Expert Rev Vaccines; 2008 Dec; 7(10):1465-73. PubMed ID: 19053203 [TBL] [Abstract][Full Text] [Related]
17. Safety and immunogenicity of the HPV-16/18 AS04-adjuvanted vaccine in HIV-positive women in South Africa: a partially-blind randomised placebo-controlled study. Denny L; Hendricks B; Gordon C; Thomas F; Hezareh M; Dobbelaere K; Durand C; Hervé C; Descamps D Vaccine; 2013 Nov; 31(48):5745-53. PubMed ID: 24091311 [TBL] [Abstract][Full Text] [Related]
18. AS04-adjuvanted human papillomavirus (HPV) types 16 and 18 vaccine (Cervarix®): a review of its use in the prevention of premalignant cervical lesions and cervical cancer causally related to certain oncogenic HPV types. McKeage K; Romanowski B Drugs; 2011 Mar; 71(4):465-88. PubMed ID: 21395359 [TBL] [Abstract][Full Text] [Related]
19. Immunogenicity and safety of the HPV-16/18 AS04-adjuvanted vaccine administered as a 2-dose schedule compared with the licensed 3-dose schedule: results from a randomized study. Romanowski B; Schwarz TF; Ferguson LM; Peters K; Dionne M; Schulze K; Ramjattan B; Hillemanns P; Catteau G; Dobbelaere K; Schuind A; Descamps D Hum Vaccin; 2011 Dec; 7(12):1374-86. PubMed ID: 22048171 [TBL] [Abstract][Full Text] [Related]
20. Efficacy of the human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical intraepithelial neoplasia and cervical infection in young Japanese women. Konno R; Yoshikawa H; Okutani M; Quint W; V Suryakiran P; Lin L; Struyf F Hum Vaccin Immunother; 2014; 10(7):1781-94. PubMed ID: 25424783 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]